ライフサイエンスコーパス: fatigue

1 ed by fever, myalgia, periorbital edema, and fatigue.

2 tity with the anticipated effect of reducing fatigue.

3 spital nurse work system to nurse coping and fatigue.

4 37 in the treatment of inflammation-mediated fatigue.

5 non-serious adverse events were headache and fatigue.

6 for mechanistic understanding of poststroke fatigue.

7 attempting to understand and predict muscle fatigue.

8 ert quantity as a surrogate marker for alert fatigue.

9 le neutropenia, gastrointestinal events, and fatigue.

10 , either spontaneous or induced by materials fatigue.

11 the caudate nucleus in relation to cognitive fatigue.

12 may be especially susceptible to quadriceps fatigue.

13 jor depression, and with unexplained chronic fatigue.

14 lead to muscle weakness and premature muscle fatigue.

15 adache, and 1,930 (25%) had higher levels of fatigue.

16 s (AEs; >5%) included anemia, pneumonia, and fatigue.

17 of breathing is needed to reduce quadriceps fatigue.

18 ences of fatigue, and barriers to addressing fatigue.

19 barriers to addressing, and consequences of fatigue.

20 onstrated the most attenuation of quadriceps fatigue.

21 al pain, chronic diarrhoea, weight loss, and fatigue.

22 sistance under moderate uniaxial tension and fatigue.

23 conditions of weakness and premature muscle fatigue.

24 ic or psychiatric comorbidity explaining the fatigue.

25 atigue severity in women with CFS and severe fatigue.

26 eathing-related changes in quadriceps muscle fatigue.

27 dings, which they argue is based on neuronal fatigue.

28 lus migraine, 1.88 (1.08, 3.25) for CRS plus fatigue, 1.95 (1.18, 3.21) for migraine plus fatigue, an

29 penia (32%), anemia (27%), leukopenia (16%), fatigue (11%), and hyponatremia (10%).

30 dache (27% of patients), diarrhea (14%), and fatigue (13%).

31 Common grade 3 or 4 adverse events included fatigue (13.1%) and febrile neutropenia (11.5%).

32 Headache (1832 [25.4%]), fatigue (1361 [18.9%]), and muscle pain (942 [13.1%]) we

33 urring in >5% of the patient population, was fatigue (14%).

34 nausea (17 [53%]), diarrhoea (16 [50%]), and fatigue (16 [50%]).

35 Grade >/= 3 related adverse events included fatigue (16%), thrombocytopenia (16%), and neutropenia (

36 6%]), leucopenia (12 [17%] vs 13 [19%]), and fatigue (17 [24%] vs 15 [21%]).

37 nts (occurring in >10% of patients) included fatigue (21 patients [40%]), influenza-like symptoms (11

38 erse events were headache (26% of patients), fatigue (21%), and nausea (17%).

39 0%] of 312), anaemia (68 [22%] vs 49 [16%]), fatigue (23 [7%] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%

40 The most common adverse events were fatigue (25%), headache (13%), upper respiratory tract i

41 y-grade treatment-related AEs (most commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash

42 up were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%

43 (7%); with IFN and octreotide, they included fatigue (27%), neutropenia (12%), and nausea (6%).

44 e events were headache (35 [21%] of 166) and fatigue (28 [17%] of 166).

45 he most common grade 3-4 adverse events were fatigue (29 [18%] of 157 patients in the sorafenib group

46 st frequent systemic reactogenic events were fatigue (29 [43%]), headache (26 [39%]), and malaise (15

47 18% of patients), nausea (8%), ascites (3%), fatigue (3%), gastric stenosis (3%), hepatic failure (3%

48 tients), anaemia (37 [12%] vs 43 [14%]), and fatigue (30 [10%] vs 35 [12%]).

49 ents than those receiving placebo, including fatigue (30% vs. 14%) and dry mouth (25% vs. 12%) in the

50 4%), blurred vision (41%), nausea (37%), and fatigue (30%) being the most commonly observed treatment

51 9%]), thrombocytopenia (41 [9%] vs 43 [9%]), fatigue (31 [7%] vs 35 [8%]), dyspnoea (29 [6%] vs ten [

52 e headache (47 [38%]), diarrhoea (38 [31%]), fatigue (34 [27%]), and myalgia (26 [21%]).

53 in reaction (47 patients [13%] vs one [1%]), fatigue (34 patients [9%] vs nine patients [5%]), and di

54 hat occurred in 10% or more of patients were fatigue (36 [30%] patients), diarrhoea (14 [12%] patient

55 Pain (4.4 of 10), fatigue (4.7 of 10), and appetite loss (4.0 of 10) were

56 lated reaction (73 [29%]; all grade 1-2) and fatigue (40 [16%]).

57 ent-related adverse events of any grade were fatigue (46 [25%] of 184 patients), infusion-related rea

58 erse events were headache (55 [23%] of 240), fatigue (47 [20%] of 240), and nausea (32 [13%] of 240).

59 The most common adverse events were fatigue (51%), headache (36%), and nausea (23%).

60 These include pain interference (52.4), fatigue (52.2), and physical function (44.1).

61 ysical function (41.1 v 46.6, respectively), fatigue (55.8 v 50.2, respectively), and pain interferen

62 cycles 1-4 were neutropenia (175 [16%]) and fatigue (56 [5%]) of the 1070 patients treated with stan

63 en) in lung cancer (pain interference, 55.5; fatigue, 57.3; depression, 51.4) and cervical cancer (an

64 utropenia (28%), diarrhea (7%), nausea (7%), fatigue (6%), and febrile neutropenia (4%).

65 tients treated with standard epirubicin, and fatigue (63 [6%]) and infection (34 [3%]) of the 1045 pa

66 ed hypertension (32%), proteinuria (9%), and fatigue (7%); with IFN and octreotide, they included fat

67 ogic adverse events (AEs) were nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight lo

68 ), thrombocytopenia (82%), anemia (74%), and fatigue (72%); however, the majority of these were grade

69 d symptoms were exertional dyspnea (78%) and fatigue (73%).

70 sed leucocyte count (103 [16%] vs 74 [20%]), fatigue (81 [13%] vs 74 [20%]), and acne or rash (52 [8%

71 hoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated aspartate aminotransferase

72 , in either treatment group (any grade) were fatigue, alopecia, diarrhoea, decreased appetite, and na

73 human pathological conditions such as in the fatigue and anorexia associated with autoimmune diseases

74 In addition to their anti-fatigue and anti-anoxia roles in traditional medicine, R

75 Nurse fatigue and attributes of nurse professional culture als

76 A relationship between Fatigue and brain activation was evident in the caudate

77 (18%) of 270 patients-most commonly grade 3 fatigue and diarrhoea, which each occurred in five patie

78 acute severe asthma with respiratory muscle fatigue and failure of medical treatment.

79 scores related to anger and fatigue, and to fatigue and guilt, between those involved/not involved i

80 Two (7%) adverse events (fatigue and headache) were deemed possibly related to tr

81 Grade 3 fatigue and hypotension were reported in two patients ea

82 Fatigue and MSDs impact psychomotor performance; therefo

83 ophysiological changes related to poststroke fatigue and put forward potential theories for mechanist

84 interventions that attempted to reduce alert fatigue and three secondary key questions that covered t

85 put due to instrument failure (e.g., fitting fatigue and trapping column failure), limiting the utili

86 otal role of amino acid catabolism in muscle fatigue and type 2 diabetes pathogenesis.

87 aditional FES techniques often lead to quick fatigue and unnatural ballistic movements.

88 GES is a safe intervention that might reduce fatigue and, to a lesser extent, physical disability for

89 fatigue, 1.95 (1.18, 3.21) for migraine plus fatigue, and 1.84 (1.08, 3.14) for all three outcomes to

90 ews on nurse fatigue levels, consequences of fatigue, and barriers to addressing fatigue.

91 may include long-term arthralgia, arthritis, fatigue, and depression.

92 nded consequences of efforts to reduce alert fatigue, and ideal alert quantity.

93 at least 10% of the patients were pruritus, fatigue, and nausea.

94 th similar nonspecific symptoms of lethargy, fatigue, and nausea.

95 stance to electromigration, thermomechanical fatigue, and other failure modes in each joint.

96 is, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, whereas edema was mo

97 index (P = 0.008); and symptoms of snoring, fatigue, and sleepiness (P < 0.001).

98 gue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD.

99 t differences in scores related to anger and fatigue, and to fatigue and guilt, between those involve

100 on is the main cause for muscle dysfunction, fatigue, and weakening of athletic ability.

101 buvir-velpatasvir-voxilaprevir plus RBV were fatigue, anemia, gastroenteritis, and nausea.

102 hospital for work-up because of generalized fatigue, anorexia, chronic diarrhea, and weight loss.

103 average PROMIS scores for pain interference, fatigue, anxiety, depression, sleep disturbance, physica

104 orted tiredness and low energy, often called fatigue, are associated with poorer physical and mental

105 loped a phenomenological model of motor unit fatigue as a tractable means to predict muscle fatigue f

106 Cognitive fatigue, assessed before and after each block, was used

107 {112}<111> texture component as a result of fatigue-assisted deformation.

108 ent-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.

109 llic components and structures are caused by fatigue at cyclic stress amplitudes much lower than the

110 Checklist Individual Strength subscale (CIS-fatigue) at 4 weeks.

111 the control test had the greatest quadriceps fatigue attenuation with hyperoxia (r(2) = 0.79, P < 0.0

112 n brain activation associated with cognitive fatigue between persons with traumatic brain injury (TBI

113 stine fumarate treatment was associated with fatigue, but no serious adverse events were reported.

114 ent for various health conditions, including fatigue, chronic inflammation, and male impotence.

115 yndrome (CFS) have similar profiles of pain, fatigue, cognitive dysfunction and exertional exhaustion

116 ntly occurring adverse events (AEs) included fatigue (combination, 59%; ipilimumab alone, 42%), chill

117 Because domain walls can be responsible for fatigue, contain localized charges intrinsically or via

118 g and to follow the initiation and growth of fatigue cracks.

119 Cancer-related fatigue (CRF) remains one of the most prevalent and trou

120 cluding dyspnea, constipation, low appetite, fatigue, depression, and anxiety.

121 Vs and NAA/Cr, over and above the effects of fatigue, depressive symptoms, physical activity, and psy

122 enhances endurance and resistance to muscle fatigue, despite reducing muscle force.

123 he most common adverse events were headache, fatigue, diarrhea, and nausea.

124 he most common adverse events were headache, fatigue, diarrhea, and nausea; diarrhea and nausea were

125 The most common adverse events were fatigue, diarrhea, muscle spasms, nausea, and bruising.

126 derwent implant reconstruction had decreased fatigue (difference, -1.4; P = .035), whereas patients w

127 s deserve attention for further research are fatigue, disorders of behaviour and mood, interventions

128 signaling is not necessary for tumor-related fatigue, dissociating this type of cancer sequela from s

129 CFS and correlated with disease severity and fatigue duration, cytokines of 192 ME/CFS patients and 3

130 Only CXCL9 (MIG) inversely correlated with fatigue duration.

131 Symptomatic fatigue during plantar flexion exercise occurs at a comm

132 racellular space, has been proposed to limit fatigue during repetitive skeletal muscle activity.

133 toms potentially compatible with AF, such as fatigue, dyspnea, and/or palpitations.

134 ab for role functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C3

135 ses, such as those based on temporally local fatigue effects, cannot explain our findings.

136 3 or 4 treatment-related adverse events were fatigue (eight [2%] of 370 patients), alkaline phosphata

137 febrile neutropenia (26 [20%] and 15 [12%]), fatigue (eight [6%] and 17 [14%]), oral mucositis (18 [1

138 Accompanying symptoms were recurrent fever, fatigue, elevated liver enzymes, abdominal pain, and sig

139 , and interventions), and "Self" (effort and fatigue, emotions, identity, and stigma).

140 end points were global QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotional problems (EM; QLQ-O

141 Fatigue failures create enormous risks for all engineere

142 Therapy was generally well tolerated, with fatigue, fevers, and chills as the most common adverse e

143 tigue as a tractable means to predict muscle fatigue for a variety of tasks and to illustrate the ind

144 l utility of the model to predict motor unit fatigue for more complicated, real-world applications.

145 tional Assessment of Chronic Illness Therapy-Fatigue for the comprehensive measure and the Profile of

146 249 patients, the most common of which were fatigue (four [2%]), and asthenia, elevated lipase, hypo

147 edema (grade 1 to 2, 37%; grade 3, 2%), and fatigue (grade 1 to 2, 37%; no grade 3 or 4) being the m

148 [6%]; grade 4, four [1%] vs two [<1%]), and fatigue (grade 3, 53 [11%] vs 41 [8%]; grade 4, three [1

149 neous tissue disorders (SSTD), diarrhea, and fatigue; grade 3 or higher AEs included dyspnea, fatigue

150 ith regards to human use and may explain why fatigue, headaches and nervousness have been reported as

151 The animals were parametrically fatigued immediately before the behavioural tasks by run

152 ating Scale for Depression of 19 or more, or Fatigue Impact Scale of 75 or more.

153 dings challenge the current understanding of fatigue in cancer patients, the most common and debilita

154 y and exacerbate exercise-induced quadriceps fatigue in healthy men.

155 Fatigue in hospital nurses is associated with decreased

156 xercise decreases the severity of quadriceps fatigue in men.

157 Addressing fatigue in nurses has been identified as a priority by m

158 important barrier to effectively addressing fatigue in nursing work systems.

159 perspectives on the importance of addressing fatigue in relation to other health systems challenges.

160 Approaches for managing alert fatigue in the ICU are provided as a result of reviewing

161 antly lower levels of anxiety/depression and fatigue in the intervention group at T2.

162 nvolves cellular mechanisms related to spike fatigue in young animals and a progressive decrease in r

163 rishness (in 23.9% and 30.5%, vs. 9.0%), and fatigue (in 14.0% and 15.4%, vs. 8.8%) (P<0.001 for all

164 We anticipated that reduction in alert fatigue, including the concept of desensitization may no

165 g and performance is often underestimated by fatigued individuals and is only beginning to be underst

166 In particular, it is unclear whether fatigue influences decision (cost-benefit) strategies fl

167 Scores on the Brief Fatigue Inventory (BFI), CLL module of the MD Anderson S

168 ort Form Survey and 20-item Multidimensional Fatigue Inventory), bladder and sexual dysfunction (Inte

169 Poststroke fatigue is a debilitating symptom and is poorly understo

170 Muscle fatigue is a temporary decline in the force and power ca

171 Standardized metrics for alert fatigue is needed to advance the field.

172 Fatigue is the most common symptom of cancer at diagnosi

173 riation in the presence of pain, rather than fatigue, is associated with neuronal alterations in the

174 Alert fatigue itself is studied less frequently, as an outcome

175 thyroid toxicity, thrombocytopenia, nausea, fatigue, jaundice, and muscle aches.

176 o the Dutch guideline: a new onset of severe fatigue lasting >/=6 months with significant disabilitie

177 omen aged 18 to 59 years with CFS and severe fatigue leading to functional impairment.

178 The most common symptoms in adults are fatigue, lethargy, cold intolerance, weight gain, consti

179 0% (5 of 25) of placebo recipients reached a fatigue level within the range reported by healthy perso

180 Our results indicate that fatigue levels can be incorporated in flexible cost-bene

181 tions eliciting participants' views on nurse fatigue levels, consequences of fatigue, and barriers to

182 dditively manufactured parts to maximise the fatigue life for a given loading cycle.

183 Without post-manufacture HIPing the fatigue life of electron beam melting (EBM) additively m

184 challenging to predict cyclic behaviour and fatigue life under a realistic load spectrum.

185 pression of Il1b in the brain while inducing fatigue-like behaviors characterized by decreased volunt

186 icant grain growth at room temperature under fatigue loading in microcrystalline grains (>/=10 mum) i

187 mposites also have exceptional resistance to fatigue loading.

188 Cartilage fatigue may be a factor in the precocious development of

189 kert scale, numeric rating scale) or a short fatigue measure were comparable to a comprehensive measu

190 Primary outcomes were fatigue (measured by the Chalder Fatigue Questionnaire)

191 rse to patient ratio and physical and mental fatigue (measured by the number of hours into a shift) r

192 We examined whether two single-item fatigue measures (i.e., Likert scale, numeric rating sca

193 ion, use of intention-to-treat analysis, and fatigue measures (WES range, -0.91 to 0.99).

194 ved increased subcortical dopamine levels in fatigued mice: a marker of individual bias to use model-

195 mon adverse events were injection-site pain, fatigue, myalgia, and headache.

196 (n = 22 [19%]), asthenia (n = 16 [14%]), and fatigue (n = 11 [10%]).

197 rgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria (n = 11; 28%), and

198 X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4).

199 Grade 3 adverse events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroidism (n=1).

200 The most common adverse events were fatigue (n=28 [19%]) and headache (n=20 [14%]).

201 yelosuppression; nonhematologic AEs included fatigue, nausea, and diarrhea.

202 most frequently reported adverse events were fatigue, nausea, headache, insomnia, and rash.

203 the relationships among nurse perceptions of fatigue, nursing professional culture, and implications

204 ociation between reduced pressure/oxygen and fatigue on high-altitude flights.

205 four [9%] in the placebo group) followed by fatigue (one [2%] person in the placebo group), fever (o

206 two [13%]), lower abdominal pain (one [7%]), fatigue (one [7%]), and influenza-like illness (one [7%]

207 and 4 AEs were hypertension (one of six) and fatigue (one of six).

208 o [2%] of 99 patients in the placebo group), fatigue or asthenia (eight [4%] vs two [2%]), and neutro

209 d whether these alterations are specific for fatigue or whether they relate to other common CFS sympt

210 improvement in two of three symptoms (pain, fatigue, or anorexia) at week 8 compared with baseline m

211 ne performance, hand use, lesion size, mood, fatigue, or whether distraction was tested during motor

212 s of material surface flaw distributions and fatigue parameters for 3 reinforced glass-ceramics (fluo

213 cts, pain, early morning stiffness duration, fatigue, patient safety issues, function, knowledge, pat

214 The exceptional strength, ductility, and fatigue performance reported in this paper are a breakth

215 ue syndrome (CFS) is characterized by severe fatigue persisting for >/=6 months and leading to consid

216 room staff from 4 medical centers rated pain/fatigue, physical, and mental performance using validate

217 s that covered the negative effects of alert fatigue, potential unintended consequences of efforts to

218 chanical bending statuses and show excellent fatigue properties during the bending cycle tests.

219 iple cycles of actuations, owing to the anti-fatigue property of the hydrogel under moderate stresses

220 with physiological macro-phenotypes such as fatigue, providing a strong association between reduced

221 em Short Form physical and mental scales and fatigue), psychological distress (Hospital Anxiety and D

222 e placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on li

223 tcomes were fatigue (measured by the Chalder Fatigue Questionnaire) and physical function (assessed b

224 ss corrosion crack (SCC) and rolling contact fatigue (RCF).

225 ents with acute Q fever will develop chronic fatigue, referred to as Q fever fatigue syndrome (QFS).

226 tumor models revealed that tumors can induce fatigue regardless of their systemic or central nervous

227 ach block, was used as a covariate to assess fatigue-related brain activation.

228 c muscle forces and, to that model, we added fatigue-related changes in MU force, contraction time, a

229 fracture toughness of bone, we explored the fatigue resistance in metastability-assisted multiphase

230 ing stiffness, strength, toughness, damping, fatigue resistance, and self-healing ability is required

231 ensity, 80% reversible compressibility, high fatigue resistance, high electrical conductivity, and ex

232 shows photochemical isomerization with high fatigue resistance.

233 acteristics are lost first, followed by fast fatigue-resistant (FR) and slow (S) MNs.

234 ed by this strategy provide guidance for all fatigue-resistant alloy design efforts.

235 ons, facilitating the subsequent creation of fatigue-resistant microstructures via simple heat treatm

236 tudy, we directly tested the hypothesis that fatigue results from propagation of tumor-induced inflam

237 essional culture that can act as barriers to fatigue risk management programs and achieving safety cu

238 res, and their emotions (anger, guilt, fear, fatigue, sadness), could inform preparation and educatio

239 s been used to characterise all the pores in fatigue samples prior to testing and to follow the initi

240 ignificant differences between groups in CIS-fatigue score at 4 weeks (mean difference, 1.5 points [9

241 ad a reduction of two units or more in worst fatigue score in past 24 hours as assessed by the BFI.

242 weeks, compared with the control group, mean fatigue score was 19.1 (SD 7.6) in the GES group and 22.

243 The most common adverse events were fatigue (seven participants [27%]), nasopharyngitis (sev

244 Primary outcome was fatigue severity at end of treatment (EOT; week 26), ass

245 t of subcutaneous anakinra versus placebo on fatigue severity in female patients with CFS.

246 gnitive-behavioral therapy (CBT) in reducing fatigue severity in patients with QFS.

247 m treatment with doxycycline does not reduce fatigue severity in QFS patients compared to placebo.

248 CBT is effective in reducing fatigue severity in QFS patients.

249 ult in a clinically significant reduction in fatigue severity in women with CFS and severe fatigue.

250 Fatigue severity was significantly lower after CBT (31.6

251 At EOT, fatigue severity was similar between doxycycline (40.8 [

252 The primary outcome was fatigue severity, measured by the Checklist Individual S

253 ateral prefrontal cortex are associated with fatigue severity, pain, psychomotor speed, and physical

254 h the Checklist Individual Strength subscale Fatigue Severity.

255 ction model predicts that these two forms of fatigue should be strongly positively correlated, a dual

256 Despite physical exercise and fatigue significantly affecting the levels of effort tha

257 common treatment-related adverse events were fatigue (six [18%] of 33 patients) and peripheral oedema

258 were: thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%] vs 19 [5%]), brain oedema (eight [2%]

259 se event; the most common adverse event were fatigue (six [24%]), nausea (six [24%]), and arthralgia

260 lkaline phosphatase (nine [4%] vs two [2%]), fatigue (six [3%] vs seven [7%]), and increased concentr

261 mmon grade 3 and grade 4 adverse events were fatigue (six [6%] in the eltrombopag group and one [2%]

262 ]), neutropenia (13 [17%] vs four [5%]), and fatigue (six [8%] vs eight [10%]).

263 ep diaries; polysomnography; and symptoms of fatigue, sleepiness, and depression.

264 cle from SPARC-deficient mice to an in vitro fatigue stimulation protocol, we find a defective force

265 epletion was limited (a condition imposed by fatiguing stimulation, long-lasting depolarization, or l

266 The high fatigue strength presented in this work is achieved by c

267 ng low-cost titanium alloys with exceptional fatigue strength via the hydrogen sintering and phase tr

268 ferior mechanical properties, especially low fatigue strength.

269 easure and the Profile of Mood States-Brief, Fatigue subscale for the short measure; and constructed

270 with nasal and sinus, migraine headache, and fatigue symptoms in a general population representative

271 and nasal and sinus, migraine headache, and fatigue symptoms in Pennsylvania.

272 rhinosinusitis (CRS), migraine headache, and fatigue symptoms.

273 Gulf War Illness (GWI) and Chronic Fatigue Syndrome (CFS) have similar profiles of pain, fa

274 Chronic fatigue syndrome (CFS) is characterized by severe fatigu

275 Chronic fatigue syndrome (CFS) remains poorly understood.

276 kine, is suspected to play a role in chronic fatigue syndrome (CFS).

277 elop chronic fatigue, referred to as Q fever fatigue syndrome (QFS).

278 ic biomarker of MMF in patients with chronic fatigue syndrome and cognitive dysfunction.

279 lth and Care Excellence criteria for chronic fatigue syndrome from two secondary-care clinics in the

280 an effective and safe treatment for chronic fatigue syndrome, but it is therapist intensive and avai

281 hysical disability for patients with chronic fatigue syndrome.

282 r postinfectious irritable bowel and chronic fatigue syndromes.

283 ne), hypertension (16 [6%] vs six [4%]), and fatigue (ten [3%] vs two [1%]).

284 chestration of MU force contributions during fatigue, that would be unattainable with current experim

285 rboplatin, and trastuzumab plus pertuzumab), fatigue (three [1%] vs seven [3%]), alanine aminotransfe

286 ll as to exhaust prey by causing involuntary fatigue through remote activation of prey muscles [4].

287 pting to concomitantly develop resistance to fatigue (through endurance-based exercise) and increased

288 onal study estimated potential for cartilage fatigue via TMJ energy densities (ED) and jaw muscle dut

289 nts associated with savolitinib were nausea, fatigue, vomiting, and peripheral edema.

290 Quadriceps fatigue was assessed by measuring force in response to f

291 ol, P < 0.05), the attenuation of quadriceps fatigue was similar between the sexes (36 +/- 4 vs. 37 +

292 of breathing, the attenuation of quadriceps fatigue was similar between the sexes.

293 common treatment-related adverse events were fatigue, weight loss, diarrhea, palmar-plantar erythrody

294 stake task, and self-reported depression and fatigue were assessed prior to LPS/placebo injection, 2

295 e negative carry-over effects from cognitive fatigue when transferring to normal vision.

296 nhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treate

297 r in humans is characterized by low mood and fatigue, which have been suggested to reflect changes in

298 ventions designed to reduce or prevent alert fatigue within clinical decision support systems.

299 d interventions that reduce or prevent alert fatigue within clinical decision support systems.

300 All nurses in the current study experienced fatigue; yet they had varying perspectives on the import